Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Tao Sun, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M Brenner, Vlado Perkovic. Circulation 2019
Times Cited: 128
Times Cited: 128
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
Times Cited: 465
Times Cited: 465
List of shared articles
Times cited
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
Alison K Wright, Matthew J Carr, Evangelos Kontopantelis, Lalantha Leelarathna, Hood Thabit, Richard Emsley, Iain Buchan, Mamas A Mamas, Tjeerd P van Staa, Naveed Sattar,[...]. Diabetes Care 2022
Alison K Wright, Matthew J Carr, Evangelos Kontopantelis, Lalantha Leelarathna, Hood Thabit, Richard Emsley, Iain Buchan, Mamas A Mamas, Tjeerd P van Staa, Naveed Sattar,[...]. Diabetes Care 2022
Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Li-Min Zhao, Ze-Lin Zhan, Jie Ning, Mei Qiu. Front Pharmacol 2022
Li-Min Zhao, Ze-Lin Zhan, Jie Ning, Mei Qiu. Front Pharmacol 2022
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita,[...]. Cardiovasc Diabetol 2022
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita,[...]. Cardiovasc Diabetol 2022
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Kåre I Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack,[...]. Diabetes Obes Metab 2021
Kåre I Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack,[...]. Diabetes Obes Metab 2021
Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
Xu-Bin Wei, Wei Wei, Liang-Liang Ding, Shu-Yan Liu. Prim Care Diabetes 2021
Xu-Bin Wei, Wei Wei, Liang-Liang Ding, Shu-Yan Liu. Prim Care Diabetes 2021
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
Mei Qiu, Liang-Liang Ding, Xu-Bin Wei, Shu-Yan Liu, Hai-Rong Zhou. J Cardiovasc Pharmacol 2021
Mei Qiu, Liang-Liang Ding, Xu-Bin Wei, Shu-Yan Liu, Hai-Rong Zhou. J Cardiovasc Pharmacol 2021
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
The impact of diabetes on heart failure development: The cardio-renal-metabolic connection.
Paul Valensi, Gaétan Prévost, Sara Pinto, Jean-Michel Halimi, Erwan Donal. Diabetes Res Clin Pract 2021
Paul Valensi, Gaétan Prévost, Sara Pinto, Jean-Michel Halimi, Erwan Donal. Diabetes Res Clin Pract 2021
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.
Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding. Endocrine 2020
Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding. Endocrine 2020